A comprehensive view of Catalent Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Catalent expands Schorndorf, Germany, facility, adding 32,000 sq ft of storage and handling for clinical supplies; new space supports temperature-controlled and FastChain demand-led supply services

Forty-eight pharma M&A deals worth €33.55B took place in Q1 2024; Novo Holdings led the top five acquisitions, with a €10.659B deal for Catalent followed by Gilead's €3.95B deal for CymaBay Therapeutics: Evaluate Pharma

Catalent to lay off approximately 130 staff in Bloomington, Indiana, fill-finish plant despite an upcoming takeover by Novo Holdings; the job cuts are part of an ongoing effort to consolidate and reduce costs across its operations

Novo Holdings acquires contract development and manufacturing organization Catalent for US$16.5B in an all-cash deal; Novo Holdings sells three Catalent manufacturing sites to Novo Nordisk for US$11.0B to boost its diabetes and obesity supply chain

JPMorgan: Novo Nordisk's acquisition of production sites through Catalent is sensible move to help meet weight loss drug demand; production capacity to be increased for injectable Wegovy and Ozempic treatments, allowing Novo to ramp supply for US, world

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count